AIxCrypto Holdings, Inc.
AIXCNasdaq
$0.78
↓ -11.9%Jul 17 close · end-of-day
Price
1Y↓ -80.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$6.0M
Enterprise Value
-$229,287.87
P/E
—
P/S
—
P/B
0.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$20.4M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-93.3%
ROIC
-74.7%
Debt / Equity
—
Net Cash
$6.2M
Return 1Y
-76.2%
Company profile
Qualigen Therapeutics, Inc. develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers.
- CEO
- Michael S. Poirier
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 50
- Headquarters
- California
- Website
- qualigeninc.com
Earnings
AIXC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.79↓ -56.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $4.3M | $5.7M | $5.0M | — | — | — |
| Gross profit | $629,517.00 | $689,236.00 | — | — | — | — |
| Operating income | — | -$22.7M | -$14.8M | -$11.3M | -$5.8M | -$13.2M |
| Net income | -$20.4M | -$17.9M | -$18.6M | -$13.4M | -$6.3M | -$17.0M |
| Diluted EPS | — | — | — | -$132.25 | -$17.55 | -$8.11 |
| Operating cash flow | — | -$14.7M | -$13.2M | -$10.3M | -$6.3M | -$7.0M |
| Free cash flow | — | -$14.9M | -$13.4M | — | — | — |
| Gross margin | 14.6% | 12.2% | — | — | — | — |
| Operating margin | — | -400.9% | -296.2% | — | — | — |
| Net margin | -474.2% | -316.6% | -374.0% | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.7M | -$1.3M | -$1.3M | -$2.7M | -$1.7M | -$1.4M | -$7.4M | -$4.3M |
| Net income | -$1.6M | -$1.8M | -$855,822.00 | -$2.6M | -$1.7M | -$2.0M | -$10.6M | -$6.1M |
| Diluted EPS | -$10.37 | -$4.70 | $15.12 | -$1.82 | -$1.00 | -$4.68 | -$0.61 | -$0.79 |
| Operating cash flow | -$1.5M | -$1.8M | -$2.3M | -$1.6M | -$1.1M | -$2.1M | -$2.1M | -$4.5M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Oct 24, 2025
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.